Clinical Trial

Efficacy and Safety of Discontinuing 5-ASA in Patients With Inflammatory Bowel Disease

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 29, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study aims to evaluate the long-term outcomes of discontinuing 5-ASA in UC and CD patients receiving stable biologic or immunomodulator therapy using a prospective cohort based in the Busan-Ulsan-Gyeongnam region. It seeks to determine whether discontinuing 5-ASA is a safe treatment strategy in modern IBD management.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-12.
Trial Details
NCT Number NCT06878495
Lead Sponsor Pusan National University Hospital
Conditions Ulcerative Colitis (UC), Crohn's Disease, Inflammatory Bowel Disease (IBD)
Enrollment 100 participants
Start Date 2025-06-15
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-29